616 related articles for article (PubMed ID: 26707818)
1. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
4. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
5. Nanotherapy Targeting the Tumor Microenvironment.
Gong BS; Wang R; Xu HX; Miao MY; Yao ZZ
Curr Cancer Drug Targets; 2019; 19(7):525-533. PubMed ID: 30569855
[TBL] [Abstract][Full Text] [Related]
6. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
7. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
8. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
Sa P; Sahoo SK; Dilnawaz F
Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
[TBL] [Abstract][Full Text] [Related]
9. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
10. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
11. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
Kibria G; Hatakeyama H; Harashima H
Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
[TBL] [Abstract][Full Text] [Related]
12. Design considerations for nanotherapeutics in oncology.
Stylianopoulos T; Jain RK
Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
[TBL] [Abstract][Full Text] [Related]
13. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery: beyond active tumour targeting.
Sagnella SM; McCarroll JA; Kavallaris M
Nanomedicine; 2014 Aug; 10(6):1131-7. PubMed ID: 24823644
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery.
van Vlerken LE; Vyas TK; Amiji MM
Pharm Res; 2007 Aug; 24(8):1405-14. PubMed ID: 17393074
[TBL] [Abstract][Full Text] [Related]
18. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
Beretta GL; Cavalieri F
Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
[TBL] [Abstract][Full Text] [Related]
19. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.
Yadav P; Ambudkar SV; Rajendra Prasad N
J Nanobiotechnology; 2022 Sep; 20(1):423. PubMed ID: 36153528
[TBL] [Abstract][Full Text] [Related]
20. Novel nanomedicines to overcome cancer multidrug resistance.
Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
